Zobrazeno 1 - 10
of 291
pro vyhledávání: '"Luis, De La Cruz"'
Autor:
Dirk Schadendorf, Caroline Robert, Reinhard Dummer, Luis de la Cruz-Merino, Paolo A Ascierto, John M Kirkwood, Georgina V Long, Jacek Mackiewicz, Richard A Scolyer, Piotr Rutkowski, Jean-Jacques Grob, Jason John Luke, Michele Del Vecchio, Mizuho Kalabis, Adnan Khattak, Matteo S Carlino, Yujie Zhao, Alexander Eggermont, Vanna Chiarion Sileni, Clemens Krepler
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 3 (2024)
Background Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) versus placebo in the phase 3 KEYNOTE-716 study of resected stage IIB or IIC melanoma. At the prespecified third inter
Externí odkaz:
https://doaj.org/article/3a3ddc48ec6449b2b77882fcccc4b11b
Autor:
Lourdes Hontecillas-Prieto, Daniel J. García-Domínguez, Natalia Palazón-Carrión, Alejandro Martín García-Sancho, Esteban Nogales-Fernández, Carlos Jiménez-Cortegana, María L. Sánchez-León, Silvia Silva-Romeiro, Rocío Flores-Campos, Fernando Carnicero-González, Eduardo Ríos-Herranz, Fátima de la Cruz-Vicente, Guillermo Rodríguez-García, Rubén Fernández-Álvarez, Natividad Martínez-Banaclocha, Josep Gumà-Padrò, José Gómez-Codina, Antonio Salar-Silvestre, Delvys Rodríguez-Abreu, Laura Gálvez-Carvajal, Jorge Labrador, María Guirado-Risueño, Mariano Provencio-Pulla, Margarita Sánchez-Beato, Lejeune Marylene, Tomás Álvaro-Naranjo, María Casanova-Espinosa, Antonio Rueda-Domínguez, Víctor Sánchez-Margalet, Luis de la Cruz-Merino
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundDiffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma worldwide. DLBCL is an aggressive disease that can be cured with upfront standard chemoimmunotherapy schedules. However, in approximately 35-40% of the patients D
Externí odkaz:
https://doaj.org/article/212d6baeaf2d4c8bb7bf0ab05ba40793
Autor:
Carlos Jiménez-Cortegana, Francisca Palomares, Gonzalo Alba, Consuelo Santa-María, Luis de la Cruz-Merino, Victor Sánchez-Margalet, Soledad López-Enríquez
Publikováno v:
Frontiers in Immunology, Vol 14 (2024)
Dendritic cells (DCs) are antigen presenting cells that link innate and adaptive immunity. DCs have been historically considered as the most effective and potent cell population to capture, process and present antigens to activate naïve T cells and
Externí odkaz:
https://doaj.org/article/ccb8fbc9b461492fbd4910a04c7bf82d
Autor:
Azael Mora-Nuñez, Héctor Santiago-Hernández, Beethoven Bravo-Medina, Anuar Beltran-Gonzalez, Jesús Flores-Payán, José Luis de la Cruz-González, Olivier Pottiez
Publikováno v:
Photonics, Vol 11, Iss 4, p 306 (2024)
We propose a spectral filter based on a plastic optical fiber with micro-holes as a low-cost, robust, and highly reproducible spectral filter. The spectral filter is explored for two configurations: a fiber extended in a straight line and a fiber opt
Externí odkaz:
https://doaj.org/article/8bd8a1c6946d4865a76fedc5fe78eaca
Autor:
Carlos Jiménez-Cortegana, Elena Salamanca, Natalia Palazón-Carrión, Flora Sánchez-Jiménez, Antonio Pérez-Pérez, Teresa Vilariño-García, Sandra Fuentes, Salomón Martín, Marta Jiménez, Raquel Galván, Carmen Rodríguez-Chacón, Catalina Sánchez-Mora, Elisa Moreno-Mellado, Belén Gutiérrez-Gutiérrez, Nerissa Álvarez, Alberto Sosa, José Garnacho-Montero, Luis de la Cruz-Merino, Jesús Rodríguez-Baño, Víctor Sánchez-Margalet
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
SARS-CoV-2 infection is the cause of the disease named COVID-19, a major public health challenge worldwide. Differences in the severity, complications and outcomes of the COVID-19 are intriguing and, patients with similar baseline clinical conditions
Externí odkaz:
https://doaj.org/article/e106077a792e43cf9b36806d4c0e7273
Autor:
Alberto Torres-Zurita, Lucía Vázquez-Montero, Laura Gallego-López, María Dolores Mediano-Rambla, Luis de la Cruz-Merino
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Nowadays, immune checkpoint inhibitors (ICI) have become the cornerstone of treatment for many tumors, either as monotherapy or in combination with other therapies. However, these drugs are associated with several new side effects that need early det
Externí odkaz:
https://doaj.org/article/e7f8dded05b14850936d2a0a4f5514ca
Autor:
Javier Salvador Bofill, Fernando Moreno Anton, Cesar Augusto Rodriguez Sanchez, Elena Galve Calvo, Cristina Hernando Melia, Eva Maria Ciruelos Gil, Maria Vidal, Begoña Jiménez-Rodriguez, Luis De la Cruz Merino, Noelia Martínez Jañez, Rafael Villanueva Vazquez, Ruben de Toro Salas, Antonio Anton Torres, Isabel Manuela Alvarez Lopez, Joaquin Gavila Gregori, Vanesa Quiroga Garcia, Elena Vicente Rubio, Juan De la Haba-Rodriguez, Santiago Gonzalez-Santiago, Nieves Diaz Fernandez, Agusti Barnadas Molins, Blanca Cantos Sanchez de Ibargüen, Juan Ignacio Delgado Mingorance, Meritxell Bellet Ezquerra, Sonia de Casa, Asuncion Gimeno, Miguel Martin
Publikováno v:
Breast, Vol 66, Iss , Pp 77-84 (2022)
Background: Breast cancer is the most common malignancy and the second leading cause of cancer-related mortality in Spanish women. Ribociclib in combination with endocrine therapy (ET) has shown superiority in prolonging survival in patients with hor
Externí odkaz:
https://doaj.org/article/dad241cf2af94fb9adb70457754b6c11
Autor:
Daniel J. García-Domínguez, Soledad López-Enríquez, Gonzalo Alba, Carmen Garnacho, Carlos Jiménez-Cortegana, Rocío Flores-Campos, Luis de la Cruz-Merino, Nabil Hajji, Víctor Sánchez-Margalet, Lourdes Hontecillas-Prieto
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 2, p 1195 (2024)
Cancer is a complex disease that, despite advances in treatment and the greater understanding of the tumor biology until today, continues to be a prevalent and lethal disease. Chemotherapy, radiotherapy, and surgery are the conventional treatments, w
Externí odkaz:
https://doaj.org/article/61ae30b5083743feb8847aabd49c9e8a
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
The development of immune checkpoint inhibitors has revolutionized the landscape of treatment of advanced melanoma in recent years. Based on the efficacy results of the phase III CheckMate 067 trial, nivolumab in combination with ipilimumab is one of
Externí odkaz:
https://doaj.org/article/420f01958705471bbfd0c7f1fc9d8bd7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.